Showing 2636 results
- 597516
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- 59751Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
- 35321In this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and…
- 35326Novartis ranks #4 in Fortune Magazine’s Most Admired Companies Pharmaceutical Industry list.
- 35336In this a16z podcast, bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis, on some questions, challenges and opportunities that we’re facing…
- 35356Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could…
- 35361Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable…
- 35371Novartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based…
- 35376Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
- 35391Novartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page